List of Zepzelca drug patents
Zepzelca is owned by Jazz.
Zepzelca contains Lurbinectedin.
Zepzelca has a total of 1 drug patent out of which 0 drug patents have expired.
Zepzelca was authorised for market use on 15 June, 2020.
Zepzelca is available in powder;intravenous dosage forms.
Zepzelca can be used as treatment of adult patients with small cell lung cancer (sclc) with disease progression on or after platinum-based chemotherapy..
Drug patent challenges can be filed against Zepzelca from 2024-06-15.
The generics of Zepzelca are possible to be released after 15 June, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7763615 | JAZZ | Ecteinascidin analogs for use as antitumour agents |
Dec, 2024
(1 year, 8 months from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 15, 2025 |
| Orphan Drug Exclusivity (ODE) | Jun 15, 2027 |
Drugs and Companies using LURBINECTEDIN ingredient
NCE-1 date: 2024-06-15
Market Authorisation Date: 15 June, 2020
Treatment: Treatment of adult patients with small cell lung cancer (sclc) with disease progression on or after platinum-based chemotherapy.
Dosage: POWDER;INTRAVENOUS
ZEPZELCA family patents
3
European Union
2
United Kingdom
2
Japan
1
Israel
1
Denmark
1
Austria
1
Mexico
1
Australia
1
Hong Kong
1
Slovenia
1
Russia
1
Hungary
1
Norway
1
Germany
1
United States
1
Portugal
1
Cyprus
1
Spain
1
Korea, Republic of
1
Poland
1
China
1
Canada
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic